BEGIN:VCALENDAR VERSION:2.0 PRODID:-//BioCT - ECPv6.3.3.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:BioCT X-ORIGINAL-URL:https://bioct.org X-WR-CALDESC:Events for BioCT REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20210314T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20211107T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20210414T110000 DTEND;TZID=America/New_York:20210414T120000 DTSTAMP:20240328T184255 CREATED:20210315T185615Z LAST-MODIFIED:20210315T185615Z UID:4507-1618398000-1618401600@bioct.org SUMMARY:Enabling the Drug Discovery & Development Continuum - Hosted by Evotec DESCRIPTION:The first webinar of the series will outline how the blending of discovery and development teams and profiling activities\, often considered only in development\, within the lead optimisation (LO) phase facilitates a gradual and seamless transition into clinically enabling development rather than a discrete hand-over between traditionally separate organisations. This philosophy has been shown to deliver PDCs with enhanced “development quality” and hence increased likelihood of surviving downstream development pressures. \nThe presentation will also describe Evotec’s approaches to make better and more informed decisions to better manage development risks through a strong focus on human relevance as well as the prediction of outcomes\, for example\, with the use of machine learning and AI. In addition\, for those outcomes that cannot be predicted\, the benefits of revealing the unpredictable as early as possible in order to discharge or mitigate development risks will be discussed. URL:https://bioct.org/event/enabling-the-drug-discovery-development-continuum-hosted-by-evotec/ END:VEVENT END:VCALENDAR